FasL Expression in ECFCs
| Experiment No. . | FasL+Cells (%) . | ECFCs/100 Cells . | ||
|---|---|---|---|---|
| Day 5 . | Day 8 . | Day 5 . | Day 8 . | |
| 1 | 58 | 56 | 62 ± 5 | 86 ± 7 |
| 2 | 61 | 94 | 66 ± 4 | 90 ± 6 |
| 3 | 99 | 69 | 67 ± 7 | 91 ± 10 |
| 4 | 47 | 50 | 65 ± 6 | 93 ± 7 |
| Mean ± SD | 66 ± 22 | 67 ± 19 | 65 ± 4 | 90 ± 3 |
| Experiment No. . | FasL+Cells (%) . | ECFCs/100 Cells . | ||
|---|---|---|---|---|
| Day 5 . | Day 8 . | Day 5 . | Day 8 . | |
| 1 | 58 | 56 | 62 ± 5 | 86 ± 7 |
| 2 | 61 | 94 | 66 ± 4 | 90 ± 6 |
| 3 | 99 | 69 | 67 ± 7 | 91 ± 10 |
| 4 | 47 | 50 | 65 ± 6 | 93 ± 7 |
| Mean ± SD | 66 ± 22 | 67 ± 19 | 65 ± 4 | 90 ± 3 |
Day-5 and derivative day-8 cells incubated without rhIFNγ were analyzed for FasL and CD71 by flow cytometry after permeabilization (experiments no. 2 through 4). In experiment no. 1, only FasL was analyzed. Aliquots of day-5 and day-8 cells were cultured in plasma clots to obtain the ECFC number among the total cells.